Line Uhrenholt

Aalborg University

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (10)

René Drage Østgård

Aarhus University

DENMARK

View details

Merete Lund Hetland

Professor

University of Copenhagen

DENMARK

View details

Peter C. Taylor

UNITED KINGDOM

View details

Anne Voss

Odense University Hospital

DENMARK

View details

Giovanni Cagnotto

Lund University

SWEDEN

View details

Kristina Lend

Karolinska Institutet

SWEDEN

View details

Mikkel Østergaard

Professor

Rigshospitalet

DENMARK

View details

Conni Skrubbeltrang

Aalborg University

DENMARK

View details

Ronald van Vollenhoven

Professor and Chief

Amsterdam UMC

NETHERLANDS

View details

Hanne Merete Lindegaard

University of Southern Denmark

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Line Uhrenholt

Research Interests

Explore related searches

Contact this professor

Articles (10)

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial

Forståelsesmodel for de targeterede sygdomsmodificerende antiinflammatoriske lægemidler

Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial

Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial

Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis

Isolation in patients with inflammatory rheumatic diseases during COVID-19 pandemic compared to healthy individuals

Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study

Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study

Collaborators (10)

René Drage Østgård

Merete Lund Hetland

Peter C. Taylor

Anne Voss

Giovanni Cagnotto

Kristina Lend

Mikkel Østergaard

Conni Skrubbeltrang

Ronald van Vollenhoven

Hanne Merete Lindegaard

Make your next move.